CTNM vs. GMTX, SNDX, TARO, DVAX, SUPN, LGND, RCUS, BLTE, AKRO, and AVDL
Should you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Gemini Therapeutics (GMTX), Syndax Pharmaceuticals (SNDX), Taro Pharmaceutical Industries (TARO), Dynavax Technologies (DVAX), Supernus Pharmaceuticals (SUPN), Ligand Pharmaceuticals (LGND), Arcus Biosciences (RCUS), Belite Bio (BLTE), Akero Therapeutics (AKRO), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical preparations" industry.
Contineum Therapeutics (NASDAQ:CTNM) and Gemini Therapeutics (NASDAQ:GMTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.
75.4% of Gemini Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Gemini Therapeutics received 16 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 63.33% of users gave Gemini Therapeutics an outperform vote.
Contineum Therapeutics' return on equity of 0.00% beat Gemini Therapeutics' return on equity.
In the previous week, Contineum Therapeutics' average media sentiment score of 0.00 equaled Gemini Therapeutics'average media sentiment score.
Contineum Therapeutics currently has a consensus price target of $28.00, suggesting a potential upside of 71.67%. Given Contineum Therapeutics' higher probable upside, research analysts clearly believe Contineum Therapeutics is more favorable than Gemini Therapeutics.
Summary
Contineum Therapeutics beats Gemini Therapeutics on 5 of the 8 factors compared between the two stocks.
Get Contineum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Contineum Therapeutics Competitors List
Related Companies and Tools
